Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciNeuro of Shanghai Launches with $100 Million for CNS Drugs

publication date: Dec 8, 2020

SciNeuro Pharma, a new Shanghai-Philadelphia company, launched with $100 million in initial funding to develop novel CNS treatments. The A round was co-led by Lilly Asia Ventures and Arch Venture Partners, and Min Li, PhD, a Venture Partner at Lilly Asia Ventures, serves as Founder and CEO of the new company. SciNeuro says it will develop new CNS treatments through internal R&D and in-licensings with an initial focus on China's market. Also participating in the A round were Boyu Capital, General Atlantic, Sequoia Capital China, TF Capital and Zoo Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital